MDT-AP-3336
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 8.2
- sex
- F
- new_clusters
- S2
- umap1_2d
- 0.13900341
- umap2_2d
- -9.403621854
- umap1_3d
- -4.154464061
- umap2_3d
- -1.334861842
- umap3_3d
- 6.079782382
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.430
- ANDROGEN_RESPONSE+0.420
- INTERFERON_ALPHA_RESPONSE+0.400
- UV_RESPONSE_DN+0.400
- G2M_CHECKPOINT+0.380
- UNFOLDED_PROTEIN_RESPONSE+0.380
- MYC_TARGETS_V1+0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- TNFA_SIGNALING_VIA_NFKB+0.320
- MYC_TARGETS_V2+0.310
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.240
- DNA_REPAIR-0.190
- ANGIOGENESIS-0.100
- HEDGEHOG_SIGNALING-0.100
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.100
- COAGULATION-0.070
- MYOGENESIS-0.060
- KRAS_SIGNALING_DN-0.050
- GLYCOLYSIS-0.040
- PEROXISOME-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_BVSW4GTG | Med | Medulloblastoma | 0.831 |
| 2 | MDT-AP-2865 | Med | Medulloblastoma | 0.825 |
| 3 | MNG638 | — | — | 0.817 |
| 4 | MDT-AP-3069 | Med | Medulloblastoma | 0.816 |
| 5 | MDT-AP-3379 | Med | Medulloblastoma | 0.803 |
| 6 | TCGA-CQ-5326-01A-01R-1873-07 | — | — | 0.788 |
| 7 | MDT-AP-3317 | Med | Medulloblastoma | 0.783 |
| 8 | MDT-AP-3056 | Med | Medulloblastoma | 0.782 |
| 9 | 4c8b5d7c-d82b-4504-9b9e-3946ca14251e | — | — | 0.781 |
| 10 | MDT-AP-3281 | Med | Medulloblastoma | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.420 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |